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FDA-approved in December 2006, during our study period. We
also reviewed charges and reimbursement data collected for the
drug from June 2006 to December 2006. For the duration of the
study period, we had a positive margin and our reimbursement to
charge rate for multiple myeloma patients was close to MDACC
goal of 55%, with 53.3% rate overall. Based on this analysis,
there were some differences between the model assumptions and
our ﬁndings from actual data. Our model had predicted 100%
usage for the FDA approved indication of multiple myeloma in
the expected patient population of 25 patients. Actual data col-
lected showed that not only did we have more than expected
number of patients on bortezomib, potentially due to the change
in labeling to an earlier stage of disease, but our model had
assumed 4 cycles of bortezomib therapy per patient whereas the
actual average number of cycles per patient was only 2 at our
institution. We did not have data to determine whether the
patients had obtained more cycles of therapy from other
providers.
Lessons Learned: Annual budget impact analysis helped estimate
the cost to the institution for adding bortezomib to the formu-
lary. Performing an annual budget impact before the addition of
a drug to an institution’s formulary, and comparing it with the
annual budget impact after a few years of the drug being on the
formulary, is an essential process in determining the best use of
scarcely available, expensive resources for the most appropriate
use. Cost effectiveness studies, that take costs of treatments and
their outcomes in patients into account, are as important in
allocating resources to best possible use in this era of rising costs
and future research will focus on calculating cost-effectiveness
speciﬁcally for the institution’s patient population.
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Problem or Issue Addressed: With the fast pace of new medical
technologies launched into the market, it is imperative to develop
a formal and methodical approach to assess and evaluate out-
comes and impacts; one that goes beyond the short-term vision of
price and volume negotiation. Although there are several agen-
cies across the globe that evaluate technologies, not always the
market can count on their results because 1) either these reports
are based on scenarios that don’t reﬂect the real situation (for
instance, a health plan in Africa considering a report about the
U.S. medical system), or 2) there is not enough time to wait for
a conclusion.
Goals: Effective coverage and Reimbursement decisions must
reﬂect the local scenarios where they happen, and new methods
to evaluate medical technologies must be in place to allow distant
markets to reach their own conclusions about health care. One
proposed answer to this problem is to bring different market
stakeholders to teamwork and develop an approach that com-
bines everyone’s expertise into an effective methodology reﬂect-
ing the local market scenario and population. In summary, to
develop a Health Technology Assessment that reﬂects the local
health care scenario and that is agile enough for a Health Plan.
Outcomes items used in the decision: Cost-effectiveness data
(literature and local), local prevalence and incidence disease
rates.
Implementation Strategy: Presentation and validation of meth-
odology to Cassi and J&J Executive Board. Communication of
new HTA process to all Cassi’s franchises and J&J divisions in
Brazil.
Results: Work in Progress. One technology assessed, another in
evaluation. Cassi hopes to decrease medical costs and improve
health care outcomes in 2008. J&J hopes to improve negotia-
tions with Cassi.
Lessons Learned: Developing nations cannot count solely on
studies performed in developed countries; they must develop
analyses that reﬂect local scenarios and markets. To improve
value for patients, one stakeholder cannot act alone. All partici-
pants must take action to improve the health care system’s
efﬁciency.
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Problem or Issue Addressed: Development of methods for eco-
nomic assessment of (mostly) new drugs and other interventions.
Goals: Provide clear, useful information to the German Federal
Joint Committee for use in the setting of ceiling prices. Meet the
special requirements of the German context, while remaining
consistent with international standards of health economic
assessment.
Outcomes items used in the decision: Plotting of the efﬁciency
frontier within a speciﬁc therapeutic area to display the position
of existing therapies and provide guidance for decisions through
demarcation of various zones for new therapies. Horizontal axis
consisting of the expected total cost per patient in Germany.
Vertical axis consisting of a cardinal scal of value tha reﬂects the
beneﬁt assessed beforehand by IQWiG.
Implementation Strategy: International Expert Panel convened to
develop the Methods. Draft Recommendations presented to
broadening circle of German experts and constituencies culmi-
nating in Public consultation in January 2008.
Results: The core Recommendations will be presented along with
their rationale, interpretation and use in guiding decision makers.
A worked out example will be used to illustrate the implications.
Lessons Learned: It is possible to develop Methods that provide
for economic evaluation within the constraints posed in
Germany. This is done by focusing on the narrower objective of
efﬁciency within a therapeutic area rather than the much loftier
goal of relative valuation across the health care system.
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Problem or Issue Addressed: There currently exists a lack of
sufﬁcient long-term cost-effectiveness data on new technologies
and new devices, in order to allow health care decision makers to
make good decisions. At the same time, the costs associated with
many of these technologies and devices have out-paced the level
of reimbursement given to the providers.
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